Hot Features
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associa... Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.01 | 0.352112676056 | 2.84 | 3.045 | 2.8 | 4063706 | 2.9188327 | CS |
| 4 | -0.235 | -7.61750405186 | 3.085 | 3.095 | 2.5702 | 3630695 | 2.77810304 | CS |
| 12 | -0.49 | -14.6706586826 | 3.34 | 3.64 | 2.56 | 3944982 | 2.92559244 | CS |
| 26 | -1.12 | -28.2115869018 | 3.97 | 6.4399 | 2.56 | 4098508 | 3.71277205 | CS |
| 52 | -0.13 | -4.36241610738 | 2.98 | 6.4399 | 2.56 | 4215918 | 3.90083307 | CS |
| 156 | -1.07 | -27.2959183673 | 3.92 | 14.84 | 2.09 | 3962145 | 6.03195421 | CS |
| 260 | -13.28 | -82.3310601364 | 16.13 | 23.49 | 2.09 | 3001645 | 6.91832774 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.